Verve Therapeutics, Inc.
Verve Therapeutics, Inc. (VERV): 4 pipeline candidates · ~52 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
52.2 months
D/E 0.30 · 0% dilution
Lead: Phase 1
4 candidates
N/A
N/A
A transparent, data-derived signal for Verve Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$101.3M
Quarterly Burn
$27.8M
Runway
52.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in Verve Therapeutics, Inc.'s pipeline?
Verve Therapeutics, Inc. (VERV) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Verve Therapeutics, Inc.'s lead drug candidate?
Verve Therapeutics, Inc.'s most advanced tracked candidate is verve-101 (Phase 1) for Heterozygous Familial Hypercholesterolemia.
What is Verve Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Verve Therapeutics, Inc. has approximately 52.2 months of cash runway.
Who is the CEO of Verve Therapeutics, Inc.?
Sekar Kathiresan, M.D. is the chief executive officer of Verve Therapeutics, Inc. (VERV).
Get the full picture on Verve Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.